JP7860958B2 - メチルcpg結合タンパク質2(mecp2)プロモータ配列を含む核酸構築体を用いた遺伝子治療 - Google Patents
メチルcpg結合タンパク質2(mecp2)プロモータ配列を含む核酸構築体を用いた遺伝子治療Info
- Publication number
- JP7860958B2 JP7860958B2 JP2023509770A JP2023509770A JP7860958B2 JP 7860958 B2 JP7860958 B2 JP 7860958B2 JP 2023509770 A JP2023509770 A JP 2023509770A JP 2023509770 A JP2023509770 A JP 2023509770A JP 7860958 B2 JP7860958 B2 JP 7860958B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- seq
- pgrn
- sequence
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064431P | 2020-08-12 | 2020-08-12 | |
| US63/064,431 | 2020-08-12 | ||
| PCT/EP2021/072365 WO2022034130A1 (en) | 2020-08-12 | 2021-08-11 | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537980A JP2023537980A (ja) | 2023-09-06 |
| JP2023537980A5 JP2023537980A5 (cg-RX-API-DMAC7.html) | 2024-07-25 |
| JP7860958B2 true JP7860958B2 (ja) | 2026-05-18 |
Family
ID=77655525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509770A Active JP7860958B2 (ja) | 2020-08-12 | 2021-08-11 | メチルcpg結合タンパク質2(mecp2)プロモータ配列を含む核酸構築体を用いた遺伝子治療 |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022131322A1 (cg-RX-API-DMAC7.html) * | 2020-12-17 | 2022-06-23 | ||
| IL312340A (en) * | 2021-10-28 | 2024-06-01 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
| JP2026509301A (ja) * | 2023-03-14 | 2026-03-17 | ユーシービー バイオファルマ エスアールエル | 遺伝子治療 |
| CN121335978A (zh) * | 2023-06-16 | 2026-01-13 | 舒泰神(北京)生物制药股份有限公司 | 一种人源MeCp2启动子及其用途 |
| WO2025213097A1 (en) * | 2024-04-05 | 2025-10-09 | The Children's Hospital Of Philadelphia | Novel gene therapy constructs for stxbp1 haploinsufficiency |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011505859A (ja) | 2007-12-21 | 2011-03-03 | ノバルティス アーゲー | 哺乳類発現ベクター |
| JP2017535266A (ja) | 2014-11-14 | 2017-11-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)を治療する組成物および方法 |
| JP2017536116A (ja) | 2014-11-21 | 2017-12-07 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 中枢神経系を標的化したaavベクター |
| JP2018500311A (ja) | 2014-12-16 | 2018-01-11 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| JP2019511570A (ja) | 2016-03-02 | 2019-04-25 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 前頭側頭型認知症の治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583402A (zh) * | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| TWI601821B (zh) * | 2016-04-15 | 2017-10-11 | 中央研究院 | 治療神經發展性疾病 |
| WO2020081490A1 (en) * | 2018-10-15 | 2020-04-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
-
2021
- 2021-08-11 MX MX2023001701A patent/MX2023001701A/es unknown
- 2021-08-11 AR ARP210102238A patent/AR123206A1/es unknown
- 2021-08-11 AU AU2021325717A patent/AU2021325717A1/en active Pending
- 2021-08-11 PH PH1/2023/550145A patent/PH12023550145A1/en unknown
- 2021-08-11 BR BR112023002374A patent/BR112023002374A2/pt unknown
- 2021-08-11 US US18/021,005 patent/US20230295657A1/en active Pending
- 2021-08-11 CA CA3188748A patent/CA3188748A1/en active Pending
- 2021-08-11 TW TW110129603A patent/TWI902867B/zh active
- 2021-08-11 EP EP21766127.1A patent/EP4196171A1/en active Pending
- 2021-08-11 PE PE2023000142A patent/PE20230914A1/es unknown
- 2021-08-11 CN CN202180056525.5A patent/CN116113441B/zh active Active
- 2021-08-11 WO PCT/EP2021/072365 patent/WO2022034130A1/en not_active Ceased
- 2021-08-11 JP JP2023509770A patent/JP7860958B2/ja active Active
- 2021-08-11 KR KR1020237007287A patent/KR20230044506A/ko active Pending
- 2021-08-11 IL IL300294A patent/IL300294A/en unknown
-
2023
- 2023-01-09 ZA ZA2023/00378A patent/ZA202300378B/en unknown
- 2023-01-16 CO CONC2023/0000444A patent/CO2023000444A2/es unknown
- 2023-02-10 CL CL2023000419A patent/CL2023000419A1/es unknown
- 2023-03-08 EC ECSENADI202316688A patent/ECSP23016688A/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011505859A (ja) | 2007-12-21 | 2011-03-03 | ノバルティス アーゲー | 哺乳類発現ベクター |
| JP2017535266A (ja) | 2014-11-14 | 2017-11-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)を治療する組成物および方法 |
| JP2017536116A (ja) | 2014-11-21 | 2017-12-07 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 中枢神経系を標的化したaavベクター |
| JP2018500311A (ja) | 2014-12-16 | 2018-01-11 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| JP2019511570A (ja) | 2016-03-02 | 2019-04-25 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 前頭側頭型認知症の治療 |
Non-Patent Citations (2)
| Title |
|---|
| Human Molecular Genetics,2005年,Vol.14, No.23,pp.3709-3722 |
| RNA,2003年,Vol.9,pp.607-617 |
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023000444A2 (es) | 2023-01-26 |
| EP4196171A1 (en) | 2023-06-21 |
| IL300294A (en) | 2023-04-01 |
| AU2021325717A1 (en) | 2023-03-02 |
| CL2023000419A1 (es) | 2023-07-21 |
| CA3188748A1 (en) | 2022-02-17 |
| PE20230914A1 (es) | 2023-06-02 |
| TW202221018A (zh) | 2022-06-01 |
| US20230295657A1 (en) | 2023-09-21 |
| WO2022034130A1 (en) | 2022-02-17 |
| CN116113441A (zh) | 2023-05-12 |
| PH12023550145A1 (en) | 2024-03-18 |
| KR20230044506A (ko) | 2023-04-04 |
| BR112023002374A2 (pt) | 2023-03-21 |
| CN116113441B (zh) | 2026-06-09 |
| AR123206A1 (es) | 2022-11-09 |
| JP2023537980A (ja) | 2023-09-06 |
| ZA202300378B (en) | 2024-04-24 |
| TWI902867B (zh) | 2025-11-01 |
| ECSP23016688A (es) | 2023-04-28 |
| MX2023001701A (es) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11060113B2 (en) | Gene therapies for lysosomal disorders | |
| US20250121092A1 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
| EP3702466B1 (en) | Products and methods for treatment of amyotrophic lateral sclerosis | |
| US20230295657A1 (en) | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences | |
| WO2023061499A1 (en) | Recombinant adeno-associated viral vectors for treating spinal muscular atrophy | |
| CA3134523A1 (en) | Compositions useful for treatment of pompe disease | |
| WO2019227219A1 (en) | Adeno-associated viral vector-mediated gene therapy for treating fragile x-associated disorders | |
| JP2022536338A (ja) | Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 | |
| AU2020217708B2 (en) | Adeno-associated virus delivery of CLN3 polynucleotide | |
| KR20230112672A (ko) | 신경변성 질환을 위한 유전자 요법 | |
| JP2026509301A (ja) | 遺伝子治療 | |
| KR20250156211A (ko) | 글루코실세라미다제 베타 1 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법 | |
| JP2024517957A (ja) | ベクター系 | |
| US20210361778A1 (en) | Adeno-associated virus compositions for ids gene transfer and methods of use thereof | |
| WO2024245120A1 (en) | Recombinant aav vectors for treating proteinopathies in central nervous system | |
| HK40098369A (en) | Products and methods for treatment of amyotrophic lateral sclerosis | |
| HK40031811B (en) | Products and methods for treatment of amyotrophic lateral sclerosis | |
| HK40031811A (en) | Products and methods for treatment of amyotrophic lateral sclerosis | |
| HK1230232B (en) | Products and methods for treatment of amyotrophic lateral sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240717 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240717 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260324 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260401 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260501 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7860958 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |